Reported adverse events with frequency of 20% or greater
| Patients, n (%) . | Obinutuzumab 1000 mg (n = 40) . | Obinutuzumab 2000 mg (n = 38) . | ||
|---|---|---|---|---|
| All grades, n (%) . | Grade 3-4, n (%) . | All grades, n (%) . | Grade 3-4, n (%) . | |
| IRR | 28 (70) | 1 (2.5) | 24 (63.2) | 0 (0) |
| Pyrexia | 16 (40) | 0 | 18 (47.4) | 1 (2.6) |
| Fatigue | 15 (37.5) | 1 (2.5) | 12 (31.6) | 2 (5.3) |
| Chills | 9 (22.5) | 1 (2.5) | 7 (18.4) | 0 |
| Nausea | 15 (37.5) | 0 | 10 (26.3) | 0 |
| Vomiting | 11 (27.5) | 1 (2.5) | 5 (13.5) | 0 |
| Dizziness | 10 (25) | 0 | 7 (18.4) | 0 |
| Headache | 11 (27.5) | 0 | 4 (10.5) | 0 |
| Neutropenia | 15 (37.5) | 12 (30) | 12 (31.6) | 12 (31.6) |
| Thrombocytopenia | 10 (25) | 6 (15) | 6 (15.8) | 4 (10.5) |
| Dyspnea | 6 (15) | 0 | 10 (26.3) | 1 (2.6) |
| Cough | 5 (12.5) | 0 | 8 (21.1) | 0 |
| Flushing | 8 (20) | 0 | 9 (23.7) | 0 |
| Patients, n (%) . | Obinutuzumab 1000 mg (n = 40) . | Obinutuzumab 2000 mg (n = 38) . | ||
|---|---|---|---|---|
| All grades, n (%) . | Grade 3-4, n (%) . | All grades, n (%) . | Grade 3-4, n (%) . | |
| IRR | 28 (70) | 1 (2.5) | 24 (63.2) | 0 (0) |
| Pyrexia | 16 (40) | 0 | 18 (47.4) | 1 (2.6) |
| Fatigue | 15 (37.5) | 1 (2.5) | 12 (31.6) | 2 (5.3) |
| Chills | 9 (22.5) | 1 (2.5) | 7 (18.4) | 0 |
| Nausea | 15 (37.5) | 0 | 10 (26.3) | 0 |
| Vomiting | 11 (27.5) | 1 (2.5) | 5 (13.5) | 0 |
| Dizziness | 10 (25) | 0 | 7 (18.4) | 0 |
| Headache | 11 (27.5) | 0 | 4 (10.5) | 0 |
| Neutropenia | 15 (37.5) | 12 (30) | 12 (31.6) | 12 (31.6) |
| Thrombocytopenia | 10 (25) | 6 (15) | 6 (15.8) | 4 (10.5) |
| Dyspnea | 6 (15) | 0 | 10 (26.3) | 1 (2.6) |
| Cough | 5 (12.5) | 0 | 8 (21.1) | 0 |
| Flushing | 8 (20) | 0 | 9 (23.7) | 0 |
Reported adverse events are by MedDRA (Medical Dictionary for Regulatory Activities) preferred terms.